0.23 USD
▼-0.26-53.56%
盘后 0.23 +2.27%
2026-11-20
市值
$3.25M
市盈率
—
EPS
-0.44
股息率
—
52 周区间
0.20 – 1.49
成交量
2.45M
Beta
1.69
目标价
3.30
52W 低 0.2052W 高 1.49
价格走势
公司简介
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in ...